Boston Scientific Corporation filed an Issuer Free Writing Prospectus on November 19, 2026, disclosing the pricing terms and conditions for a $3,000,000,000 four-tranche senior notes offering traded on a T+7 settlement cycle.

Key Highlights

  • Total offering size: $3,000,000,000 in senior notes across four fixed-rate tranches of 3, 5, 7, and 10 years.
  • Tranche principal amounts: $1,000,000,000 (3-year), $750,000,000 (5-year), $750,000,000 (7-year), and $500,000,000 (10-year), according to the filing.
  • Coupons range from 5.375% to 5.875%: The 3-year carries 5.375% per annum and the 10-year carries 5.875% per annum.
  • Primary use of proceeds: The company disclosed that net proceeds are intended to finance the cash consideration payable in connection with the Penumbra Acquisition and to pay related fees and expenses.
  • Special mandatory redemption: If the Penumbra Acquisition is not completed or the company notifies the trustee it will not pursue completion, each series must be redeemed at 101% of aggregate principal plus accrued and unpaid interest.
  • Concurrent euro-denominated offering: American Medical Systems Europe B.V., described as a wholly owned indirect subsidiary, priced a separate multi-tranche Euro Notes offering on the same date, totaling multiple series in euros.
  • Ratings: The notes were rated A3 by Moody's, A- by S&P (Negative outlook), and A- by Fitch (Stable outlook), as stated in the filing.

Boston Scientific's $3 Billion Senior Notes: Pricing Terms, Acquisition Link, and Redemption Provisions

According to the filing, Boston Scientific Corporation priced four tranches of senior notes on November 19, 2026, with settlement expected on December 1, 2026 (T+7). The 3-year tranche ($1,000,000,000) carries a coupon of 5.375% per annum and a yield to maturity of 5.449%, priced at 99.798% of par, with a spread of 62 basis points over the 4.625% U.S. Treasury due November 15, 2029. The 5-year tranche ($750,000,000) is priced at 99.582%, with a 5.500% coupon, a yield of 5.597%, and a spread of 72 basis points over the benchmark Treasury.

The 7-year tranche ($750,000,000) carries a coupon of 5.750% per annum, a yield of 5.755%, and is priced at 99.972%, with a spread of 80 basis points over benchmark. The 10-year tranche ($500,000,000) carries a coupon of 5.875%, a yield of 5.914%, a price of 99.709%, and a spread of 85 basis points, the filing states. All four tranches pay interest semi-annually on June 1 and December 1, with the first payment on June 1, 2027. Each tranche includes a make-whole call provision and a par call option, as well as a change of control repurchase event putable at 101% of aggregate principal plus accrued and unpaid interest.

The filing states the company intends to use net proceeds, together with any net proceeds from the concurrent Euro Notes offering, short-term borrowings and/or borrowings under credit agreements, and cash on hand, to finance the cash consideration for the Penumbra Acquisition and pay related fees and expenses. Joint bookrunners include BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Barclays Capital Inc., Morgan Stanley and Co. LLC, and Wells Fargo Securities, LLC, with eight co-managers also listed. The offering is SEC-registered under Registration Statement No. 333-285032.

What Was Disclosed

Boston Scientific Corporation filed pricing terms for a $3,000,000,000 four-tranche senior notes offering dated November 19, 2026, disclosing coupons, yields, spreads, redemption provisions, and the intended use of proceeds to fund the Penumbra Acquisition.